Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce hospitalization for heart failure.

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce hospitalization for heart failure.

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.